| :: interface biologics |
Interface Biologics develops transformative polymer based technologies that
About Interface Biologics Inc., Interface Biologics Inc. Company List · List of Companies | Companies | Sell/Buy Offers · Login | Register Free | Add My
Interface Biologics, Inc. Product Pipeline Analysis Interface Biologics, Inc. Product Pipeline Analysis Summary This report is an insightful source
Interface Biologics Announces $7M Financing (press release). nterface Biologics Inc. (IBI), a privately held commercial stage developer of
Interface Biologics, Inc., a biomedical company, secured CAD1m ($0.98m) in venture financing round. The investment was provided by The
16 /CNW/ - In a head to head comparison of Interface Biologics Inc. (IBI) Endexo Anti-thrombic additives versus commercially available heparin
4.1.1 Jun 05, 2008: Interface Biologics Inc. Achieves Reductions In Platelet Adhesion
Interface Biologics, Inc. Product Pipeline Analysis, published January 2009, pages 23, Interface Biologics, Inc. Product Pipeline Analysis Summary This report is
Interface Biologics, INC (IBI) is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the
Interface Biologics: Located in Toronto, Canada, Interface Biologics is a therapeutic biomaterials company focused on producing the next generation of smart,
Patent Number, Title Of Patent, Date Issued. 8071683 · Surface modifying macromolecules with high degradation temperatures and uses
A community that provides a rich information resource for professionals working with and in tissue and cell biobanks, biological therapeutics
Interface Biologics, Inc. As the outsourced head of marketing, developed their awareness and credibility through brand collateral including website, brochures
Interface Biologics, Toronto, Ontario. ➢ Implemed, Inc, Watertown, MA. ➢ InfraMed Imaging, LLC, Victor, Montana. ➢ InfraRed Imaging Systems, Columbus , OH
Interface Biologics Announces $5 Million Financing and Appointment of Thomas P. Reeves as President & CEO.
Health care industry insiders provide analysis & data on pharma biotech device & diagnostic company strategy & trends. Deals & technology
Interface Biologics: Interface Biologics; MyVoice: MyVoice. Commercialization and knowledge transfer are about creating connections and forming partnerships .
Research about Heart Interface Corp., including news, information, and reports with SpectraScience [SCIE], LoneStar Heart, Interface Biologics, NeoGenomics
Interface Biologics, Inc. Product Pipeline Analysis Summary This report is an insightful source for data, analysis and strategic insights into a Scope s pipeline
INTERFACE BIOLOGICS - write and read reviews and find brand information for products and services associated with the INTERFACE BIOLOGICS trademark.
Interface Biologics, Inc., a Toronto, Canada-based commercial stage developer of innovative biomedical-polymer products, completed a $7m
Tom Reeves, President & CEO of Interface Biologics said, "We're very Interface Biologics is a commercial stage privately held company that
News for Medical Sales & Marketing professionals and Independent Sales Representatives: Interface Biologics Announces $7M Financing.
Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and
Interface Biologics Inc. Interface Biologics, Fresenius Medical Care Sign License Agreement.
Interface Biologics, Inc. key employees list from Pharmaceutical Business Review .
MFRC and NATASHA'S WOOD“ FOUNDATION ANNOUNCE CHILDREN'S ART CONTEST IN SUPPORT OF MILITARY FAMILIES. Ottawa
Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, announces a $1
Interface Biologics Inc., Ontario. Ionalytics Corporation, Ontario. Zelos Therapeutics Inc., Ontario. 2002/2003. Ægera Therapeutics Inc., Ontario/Québec. Affinium
Interface Biologics' goal is to design innovative biomaterials for inclusion in health care products. They are specifically engaged in the application of novel
Interfacebiologics: Interface Biologics - INVESTORS Interface Biologics Inc. - Interface Biologics Secures Seed Financing 2009/5/19. Bunmi Dosunmu, VP
Interface Biologics Inc., or IBI, a therapeutic biomaterials company, has announced the signing of a joint development agreement with BASF
TORONTO, ONTARIO-- - Interface Biologics Inc. , a privately held commercial stage developer of transformative biomedical-polymer products,
Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, has announced the
stockholder: Cardiomind, Interface Biologics, Aritech, DSI/Transoma, InstyMeds, Intervalve, Medtronic, Osprey Medical, Stout. Medical, Tricardia
Interface Biologics, Fresenius Medical Care Sign License Agreement [July 20, 2010 - 05:27 AM PST]: Interface Biologics, Fresenius Medical
Find all about polymer additives and masterbatches on SpecialChem4Polymers. com, the best resource on plastics and rubber additives.
Trademark information for INTERFACE BIOLOGICS, owned by INTERFACE BIOLOGICS INC
Arthur L. Rosenthal, CEO Cappella Inc. & Chair, Interface Biologics Dr. Rosenthal is currently CEO of Cappella, Inc., a medical device company focused on
Interface's detailed financings; Comprehensive pipeline breakdown, including molecular targets & partnerships. 17 years of in-depth BioPharma industry
Interface Biologics Inc. (IBI) is a privately held, early-stage company that develops transformative biomedical polymer technology to improve the
Everything you need to know about Interface Biologics Inc. Employees - Professional Experience,Email,Phone numbers..Everything!: Professional Experience
At Lonza Biologics, Inc., designed and developed interfaces between SAP and Metler-Toledo systems to capture data between systems and update SAP with
About Us Our Products Prices & Performance Resource Centre
Interface Biologics, Inc. - US patent applications assigned to Interface Biologics, Inc..
Tom Reeves, President and CEO of Interface Biologics mentioned that “We've been working with Navilyst Health-related considering that
27 Jul 2011 Executive Vice Chairman of Cappella, Inc., a medical device company focused on coronary artery disease, Chair of Interface Biologics, Inc.,
INTERFACE BIOLOGICS, INC. (IBI) is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve
Interface Biologics receives the financing as the result of a report by the Ontario Bioscience Industry Organization (TM) (OBIO(TM)) that was
Dialysis products and services provider Fresenius Medical Care and biomedical- polymer products developer Interface Biologics Inc.
Navilyst Medical licenses Endexo from Interface Biologics on Strategic Transactions, Oct-01-2011.
Camera, Canon EOS 20D. Exposure, 0.017 sec (1/60). Aperture, f/4.0. Focal Length, 23 mm. ISO Speed, 400. Exposure Bias, 0 EV. Flash, On
9 /PRNewswire/ - Interface Biologics Inc. - a privately held developer “We are fully committed to Interface Biologics and are excited about the
Interface Biologics, Toronto, ON To combat this source of infection, a Toronto- based company, Interface Biologics, has developed an ingenious method of
Jeannette Ho, Director of Operations, Interface Biologics of Interface Biologics''s information - including email, business address, business phone, biography,
Are you looking for interface biologics ? Get details of interface biologics.We provide most tagged page list related with interface biologics and more.
Interface Biologics Receives ISO 13485:2003 Certification.
Toronto, Canada â “ August 26, 2005 - Interface Biologics Inc. announced today the appointment of Richard W. Sullivan to the position of
Ontario, Canada-based Interface Biologics landed $1 million in financing to fund clinical trials after a report by the Ontario Bioscience Industry
Ten years later, came the birth of Interface Biologics Inc. (IBI) and the development of three innovative technologies that are revolutionizing the medical device
Interface Biologics Inc. company research & investing information. Find executives and the latest company news.
BDC Venture Capital Group investment in Interface Biologics Inc (79384). Submitted by pseps on 6 August 2011 - 11:55pm
Fresenius Medical Care has signed a deal to evaluate Interface Biologics Inc.'s Endexo technology, which is an alternative to heparin coatings
Legal Entity Type Code Description, Corporation. Party Name, Interface Biologics Inc. Address, MaRs Centre, South Tower 101 College Street, Suite 300
See what Interface Biologics employees are currently earning. Interface Biologics Salaries, Interface Biologics Reviews, Interface Biologics Hiring Trends,
Interface Biologics Inc Product Pipeline Analysis This report is an insightful source for data, analysis and strategic insights into a Scope's pipeline and
Interface Biologics has signed a definitive licence and supply agreement with Navilyst Medical, a leading manufacturer of image-guided
Interface Biologics is a commercial stage privately held company that develops For more information about Interface Biologics, please visit
Grants management and CRM solution. Interface Biologics Inc. Information Technology; (Proactive Network Monitoring & support). Mental Health Commission of
News: Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to
Interface Biologics Closes $10 Million Financing 10/19/2005 5:11:58 PM More Interface Biologics Appoints New President And CEO 10/19/2005 5:09:11 PM
INTERFACE BIOLOGICS, INC. (IBI) is a privately held early commercial stage company that develops transformative biomedical polymer
ONTARIO--(Marketwire - July 12, 2011) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer
16 /PRNewswire/ -- In a head to head comparison of Interface Biologics Inc. (IBI) Endexo Anti-thrombic additives versus commercially available
Interface Biologics Closes 5mm Financing and Appoints Thomas P. Reeves President andCEO Toronto - December 9, 2008 - FOR IMMEDIATE
Find out Interface Biologics, Inc. locations and subsidiaries from Pharmaceutical Business Review.
Closely held Interface Biologics has reached a definitive license and supply agreement with Navilyst Medical, giving it exclusive access to
Kevin Palmer, Interface Biologics Inc., Toronto, ON - Business Contact Information in Jigsaw's business directory. Jigsaw's business directory provides complete
Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer.
Interface Biologics is a therapeutic biomaterials company focused on producing the next generation of smart, implantable, bioresorbable medical devices for use
Toronto-based Interface Biologics raised. $10 million in Series A equity financing this past fall shortly before the third anniver- sary of its founding. How did the
The Interface Biologics Story Hear from the Founder (Prof. Paul Santerre), the Founding VC (Genesys Capital), and the Professional CEO (Rick
In a head to head comparison of Interface Biologics Inc. (IBI) Endexo Anti- thrombic additives versus commercially available heparin coated
IBM Global Business Services. IGY Immune Technologies and Life Sciences Inc. Induce Biologics Inc. Industry Canada. Interface Biologics Inc.
Interface Biologics Receives ISO 13485:2003 Certification 10/26/2010 10:06:50 Interface Biologics Secures $5M Financing and Appoints Thomas P. Reeves
Watch Interface Biologics Inc. Videos. Free Streaming Interface Biologics Inc. Video Clips.
20 /PRNewswire/ - Interface Biologics Inc., Toronto, Ontario, is very pleased to announce the addition of Dr. Nicolas Chronos, M.D. to its Advisory Board.
TORONTO, ONTARIO, Jan 04 (MARKET WIRE) -- Interface Biologics Inc. (IBI), a privately held commercial stagedeveloper of transformative
Interface Biologics Incorporated,Interface Biologics develops medical devices that incorporate biopharmaceuticals and therapeutic agents. The focus is to build
Company profile for Interface Biologics Inc. in Toronto,ON. Get accurate business information including key contacts, company financials and more in the
TORONTO, CANADA--(Marketwire - Oct. 25, 2011) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative
Ian Parrag, a research and development scientist at Interface Biologics. works on development of an innovative drug delivery system in the lab
Interface Biologics' Anti-Thrombic Additives Show Equivalent Efficacy toCommercial Heparinized CoatingsTORONTO, Sept. 16 /PRNewswire/
Interface Biologics Inc. (IBI), a developer of transformative biomedical-polymer technology products, entered into a licensing agreement with
Directory of 15843 dialysis centers in 161 countries, Holiday Dialysis, Dialysis Holidays,Dialysis Travel Specialists, Travel Tips and Stories, Dialysis Centre
Interface Biologics Announces Reductions in Platelet Adhesion Similar to Heparin Coated Devices with Use of Non Drug Surface Additive.
Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer PR Newswire TORONTO, Dec. 9 TORONTO
Description: Interface Biologics is a privately held early commercial stage company that develops transformative biomedical polymer
Interface Biologics The company was founded in December 2001 in Toronto, Canada, and is focused on designing the next generation of smart implantable.
TORONTO, CANADA, Jan 10 (MARKET WIRE) -- Interface Biologics Inc. (IBI), a privately held commercial stagedeveloper of transformative
The trademark INTERFACE BIOLOGICS was filed on 2011-03-03 and assigned serial number 85256954.
16 - In a head to head comparison of Interface Biologics Inc. (IBI) Endexo Anti- thrombic additives versus commercially available heparin coated
Interface Biologics receives the financing as the result of a report by the Ontario Bioscience Industry Organization™ (OBIO™) that was
Interface Biologics Announces Licensing Agreement With Navilyst Medical. Internet Wire, 2011-10-25, English, Article; Other article, Online (conditions apply)
Interface Biologics closes $5 Million financing -Technology news- Toronto: Interface Biologics, a privately held developer of novel
TORONTO - Interface Biologics Inc., a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to
TORONTO, ONTARIO--(Marketwire - 07/20/10) - Interface Biologics Inc. (IBI), a privately held early commercial stage developer of transformative
The Ontario Government's Investment Accelerator Fund-Life Sciences (IAF-LS), which helps accelerate the growth of life sciences companies in
TORONTO, ONTARIO-- Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer
Interface Biologics Inc. - a privately held developer of novel "We are fully committed to Interface Biologics and are excited about the continued
Interface Biologics Receives ISO 13485:2003 Certification. IBI's primary technology focus areas are anti-thrombogenic devices that reduce thrombosis without
Interface Biologics has an integrated approach to solving mechanical and biological problems by designing the solution within the biomaterial. This unique
9.3.5 Oct 26, 2010: Interface Biologics Receives ISO 13485: 2003 Certification
Interface Biologics Inc. Company & Business Contact information- Jigsaw Business Directory. Get complete contact & company information with emails and
Interface Biologics® is a registered trademark used for Biomaterials, Namely, Surface Modifying Macro-Molecules For Incorporation Into
Interface Biologics, Inc. key employees list from Medical Devices Business Review.
Interface Biologics - Developer of innovative biomaterials. the cutting edge technologies have launched a new generation of combination medical devices.
INTERFACE BIOLOGICS. LIVE (Circa: 2011). Goods and Services: Development of biomaterials, surface modifying molecules and polymers for use Primary
Find out Interface Biologics, Inc. locations and subsidiaries from Medical Devices Business Review.
Interface Biologics licenses Endexo to Fresenius | BioTuesday "We have been impressed with what we have seen of the Endexo technology to date," Conor
LE CRFM ET LA FONDATION NATASHA'S WOODÒ ANNOUNCENT LE LANCEMENT D'UN CONCOURS DE DESSIN POUR ENFANTS AFIN D' APPUYER LES
Investor Attendees, Sample Portfolio Companies. 21 Ventures
Fresenius Medical Care (NYSE:FMS), the world's largest integrated provider of dialysis products and services, has executed an option for an
Convergent Product Development: Select company activities
Interface Biologics Announces Licensing Agreement With Navilyst Medical. Marketwire Canada, 2011-10-25, English, Article; Other article, Online ( conditions
Interface Biologics Inc company profile in Toronto, Canada. Our company profile report for Interface Biologics Inc includes business information such as contact,
Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to
TORONTO, ONTARIO Marketwire 072010 Interface Biologics Inc. IBI, a privately held early commercial stage developer of transformative
Fresenius Medical Care Executes Exclusive Interface Biologics License Agreement. Internet Wire, 2011-07-12, English, Article; Other article, Online ( conditions
Interface Biologics, Inc. Company Profile - View the latest news, market research, credit research, and investment research on Interface Biologics, Inc. Toronto
Lily currently sits as a Director on the Boards of BTE Technologies Inc., Interface Biologics Inc., Trillium Therapeutics Inc., Cytochroma Inc.,
An excerpt of an interview between MARK STEEDMAN - INTERFACE BIOLOGICS INC and The Wall Street Transcript.
Interface Biologics Inc. (IBI), a developer of transformative biomedical-polymer products, entered into a licensing and supply agreement with
Click for automatic bibliography generation Help. Assignee: INTERFACE BIOLOGICS, INC. (300-101 College Street, MaRS South TowerToront,
TORONTO, CANADA-- - Interface Biologics Inc. , a privately held commercial stage developer of transformative biomedical-polymer products,
Posted: 6/22/11 Apply through this employer's website. Interface Biologics Toronto Job Shop jobs - TorontoJobShop.ca Analytical Chemist Jobs
Flash Player is required to view this presentation, but it appears that you do not have it installed. Please visit Adobe's website at
We are fully committed to Interface Biologics and are excited about t The fact that Interface has been able to raise a significant new roun
Interface Biologics, Inc. (Toronto, ON, CA). Primary Class: 210/507. Other Classes: 55/524, 128/849, 442/79. International Classes: B32B27/02
Dr. Robert Schwartz declared the following relationships - stockholder: Cardiomind, Interface Biologics, Aritech, DSI/Transoma,. InstyMeds
Contact Bernadette Ilagan, Chemical Engineer at Interface Biologics Inc., part of Medical Devices & Equipment industry in Toronto, ON, as well as other sales
Interface Biologics Inc. Microbix Biosystems, Inc. Ogilvy Renault LLP. Paladin Labs Inc. Sanofi Pasteur Ltd. Smart & Biggar/Fetherstonhaugh. Richard Cherney,
Interface Biologics Incoperates as a biomaterials companyThe company develops and markets polymer technologies that are programmed at
Interface Biologics, Fresenius Medical Care Sign License Agreement - Interface Interface Biologics Inc. (IBI), a privately held commercial stage developer of
Legal Entity Type Code, 03. Legal Entity Type Code Description, Corporation. Party Name, Interface Biologics Inc. Address, 200 Front Street West, Suite 3004
Interface Biologics (IBI) has successfully navigated these challenges and raised over $25 million to support its R&D and commercialization
Interface Biologics. No Description Available. Business Categories: Life Sciences - Pharmaceutical & Biotechnology. Search Interactive Map. Sponsor Logo
Brash can be found in some of Canada's most successful biomedical companies including Interface Biologics Inc. of Toronto and Angiotech Inc.
Interface Biologics Inc. - a privately held developer of novel biomedical-polymers for use in implantable medical devices - is announcing that it
Interface Biologics, Inc. 9:50. Protomed. 10:00 CorInnova. 10:10 HPF GmbH. 10: 20 Vascular Magnetics, Inc. 10:30 Soft Tissue Regeneration, Inc. 10:40 VertiFlex
This has given University of Toronto spin-off company, Interface Biologics Inc (IBI) , which he co-founded in 2001, three core platform technologies and a full
NAEJA PHARMACEUTICAL INC. “Their service, delivery and sales team works perfectly together.” FAN GU,. INTERFACE BIOLOGICS INC. Trust. Quality.
Word Mark, INTERFACE BIOLOGICS. Status Code, 653. Status, Suspension letter-Mailed. Status Date, 2011-12-08. Serial Number, 85256954. Filing Date
Interface Biologics, a developer of biomedical-polymer technology products, has signed an evaluation and exclusive license option agreement
Interface Biologics Inc., Thomas P. Reeves.
Fresenius Medical Care has executed its option of an exclusive licensing agreement with Interface Biologics Inc. (IBI) following a successful
INTERFACE BIOLOGICS INC is a Reseach and Development in the Physical, Engineering, and Life Sciences (except Biotechnology) company located in
Please login or register for a new account. Presentation Info. Interface Biologics Inc. Dr. Paul Santerre, Director. 1/25/2010 300 views. Share. URL. Embed
About Interface Biologics: Interface Biologics is a biomaterials company based in Toronto, Canada , developing proprietary, nano-engineered
BioSpace Login. Enter your BioSpace account email address and password to log in now. Email Address. Password. Keep me logged in
Lily currently sits as a Director on the Boards of BTE Technologies Inc., Interface Biologics Inc., Trillium Therapeutics Inc., Cytochroma Inc., Zelos Therapeutics
Interface Biologics's investors who have provided funding to the company include - BDC Venture Capital, Covington Capital, VG Partners, . Investors in Interface
Fresh from a potentially game-changing licensing deal with dialysis industry leader Fresenius Medical Care (FSE:FME; NYSE:FMS), closely
From the wire: Toronto-based Interface Biologics develops implant coatings designed to prevent blood clots, inhibit infection and deliver drugs.
At work developing transformative biomedical-polymer products, Interface Biologics, a private company, has recently completed a $7M series B
TORONTO, Aug. 20 /PRNewswire/ — Interface Biologics Inc., Toronto, Ontario, is very pleased to announce the addition of Dr. Nicolas Chronos
Tom Reeves, President and CEO of Interface Biologics stated that "We've been working with Navilyst Medical since November of 2009 and
Interface Biologics Inc. , a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce a
Market Wire — TORONTO, CANADA--(Marketwire - Oct. 25, 2011) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative
Interface Biologics Announces $7M Financing (press release) nterface Biologics Inc. (IBI), a privately held commercial stage developer of
Interface Biologics Toronto, corporate profile and product articles.
11 Jan 2011 macular degeneration company VisionCare Ophthalmic Technologies raised $31 million; biomedical polymer company Interface Biologics
Interface Biologics, Inc. Tom Reeves, June 1, 2011, Wed, Jun 01, Company Presentation Room 1, 11:30 AM. Kane Biotech Inc, Gord Froehlich, June 1, 2011
Interface Biologics is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and
TORONTO Sept. 16 / In a head to head comparison ofI Due to the recent contamination subsequent price increases andsafeThe blood loop
Interface Biologics Inc in Toronto with phone number, address, and interactive map. Call Interface Biologics Inc now free of charge or write a review.
6172/CHENP/2008 - Published: 2009-03-27 - INTERFACE BIOLOGICS INCORPORATED. GRAFTED POLYMERS AND USES THEREOF Abstract of the
Dr. Rosenthal originally joined Interface Biologics Board in March, 2010. "We are delighted to have Art accept the position of Chairman of our
Results 1 - 10 $1 million in VC cash for Interface Biologics. Online on February 4, 2002. Toronto startup Interface Biologics, a biotechnology firm just a month old,
Posted: 7/23/11 Apply through this employer's website. Interface Biologics Toronto Job Shop jobs - TorontoJobShop.ca Analytical Chemist Jobs
INTERFACE BIOLOGICS INCORPORATED - US patent applications assigned to INTERFACE BIOLOGICS INCORPORATED.
Denis Ho, Managing Director of Life Sciences, BDC Venture Capital concluded that, "the Interface Biologics team has demonstrated strong
Interface Biologics Inc. (IBI), a privately held commercial stage developer "the Interface Biologics team has demonstrated strong commercial
Most recently, Sullivan served as CEO of Interface Biologics Inc. in Toronto. Wichita State… Wichita Business Journal 9/17/2010. Viewing Page. of; 1. 2 Articles
TORONTO, June 5 /PRNewswire/ - Medical device manufacturers are seeking alternatives to contaminated heparin coatings used to prevent
29 /PRNewswire/ -- Interface Biologics Inc. announced today the appointment of Richard W. Sullivan to the position of President and Chief
Fresenius Medical Care Executes Exclusive Interface Biologics License Agreement - MarketWatch (press release), PDF · Print
Free Online Library: Interface Biologics Inc. by "PR Newswire"; Business News, opinion and commentary Medical equipment and supplies
TORONTO, ONTARIO--(Marketwire - October 26, 2010) - Interface Biologics Inc. ( IBI), a privately held early commercial stage developer of
Interface Biologics pumpkin. Halloween at MaRS meant the Fourth Annual Pumpkin Carving Contest! The level of carving and creativity
Interfacebiologics: Interface Biologics - INVESTORS.
Contact Biomet Biologics The optimum interface point is found regardless of the hematocrit of the patient, ensuring a consistently high platelet count for each
Interface Biologics, a Toronto, Ontario, Canada-based biomedical company, has received $1m in financing. The company, which received the
Interface Biologics, Inc. Product Pipeline Analysis Summary This report is an insightful source for data, analysis and strategic insights into a Scope's pipeline and
Based in Toronto, Interface Biologics Inc. offers coatings for implantable medical devices to prevent rejection, supply time-released medications—and even
Interface Biologics Announces $7M Financing. Press release distribution provided by IPO News Today.
12 Dec 2011 Cyclacel Pharmaceuticals [CYCC], SpectraScience [SCIE], LoneStar Heart, Interface Biologics, NeoGenomics [NGNM], Vigilant Biosciences,
View Interface Biologics's recent news, press releases and events about new products, new hires, business development deals and customers..
The Business Journals National News Interface Biologics Inc. The Business Journals National News Toronto, On The Business Journals National News Toronto
University Professor of Engineering and Medicine at Interface Biologics · Join Spoke to learn more information employees in Interface Biologics · Join to view
Interface Biologics, Inc. Product Pipeline AnalysisSummaryThis report is an insightful source for data, analysis and strategic insights into a
Google: Interface Biologics. He just talked about his career path, the constant choice between industry and academia, and how he eventually ended up where
TORONTO, ONTARIO (MARKET WIRE) 07/12/11 Interface Biologics Inc. Interface Biologics is a commercial stage privately held company
Interface Biologics, Inc. develops biomedical polymer technology to improve the safety and effectiveness of medical devices, especially those that reduce
INTERFACE BIOLOGICS has named Nicolas INTERFACE BIOLOGICS has named Nicolas View this article FREE - Now for a Limited
Find local business Interface Biologics Inc. in Toronto Mississauga Brampton Oakville Etobicoke North York Scarborough GTA Ontario.
Interface Biologics Inc. operates as a biomaterials company. The company develops and markets polymer technologies that are programmed at the.
User Interface. Interactive query and analysis interface. As a web-based application, Genedata Biologics can be accessed by any client computer connected to
Consulting Advisor, Interface Biologics Inc. 0. 0 Dr. Michael J. Tolentino, M.D., serves as Consulting Advisor of Interface Biologics Inc. Dr. Tolentino is a
Prior to joining Interface Biologics, Sanjoy worked at Dabur Pharma, . Interface Biologics, Inc. has developed key technologies that are transforming medical
Private Equity Hub (peHub) is an interactive forum for the private equity community, which includes venture capitalists, buyouts professionals,
View all Topics | View all Messages < Newer Topic | Older Topic >. BioTuesdays: Fresenius executes pact for Interface Biologics license 12-Jul-11 03:39 pm
Interface Biologics Inc. (IBI) is a privately held biomaterials company located in Toronto, Canada. The company develops and markets cutting
Finance: TORONTO, CANADA-- - Interface Biologics Inc. , a privately held commercial stage developer of transformative biomedical-polymer
Interface Biologics Inc. announced that Bradley Strauss, M.D., Ph.D., FACC, presented data for the KinesyxTM bioactive oligomer technology for stent coating at
This selection is a multifunctional scientific exercise requiring a focused and integrated team operating across the R&D interface. Biologics
Interface Biologics Inc. offers anti-thrombogenic device, a self-locating fluoro- oligomer additive that passivates the surfaces of medical polymers and reduces
Interface Biologics, Inc. IRIS International, Inc. * Johnson & Johnson. KRONUS, Inc. Maine Standards Company, LLC. Medtronic, Inc. Nanosphere, Inc. Neogenix
Overview: Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety
Get Interface Biologics Inc. business contacts for Healthcare,
Interface Biologics closes $5 Million financing -Startups news- Toronto: Interface Biologics, a privately held developer of novel
Interface Biologics: Interface Biologics Inc. (IBI) is a privately held, early-stage company that develops transformative biomedical polymer
Under this agreement, Navilyst Medical has exclusive access to incorporate IBI's Endexo™ technology in its vascular access products.
U of T spin-off company, Interface Biologics Inc. (IBI), founded by Professor Paul Santerre (Director, IBBME), continues to garner technical and
Tag Archives: Interface Biologics and Personalized Medicine · Follow-On Biologics (aka Biosimilars, Subsequent Entry Biologics) · Synthetic
Canada's Voice For Biotechnology. Who We Are · Overview
We've been encouraged by the results from our evaluation period and look forward to working with Interface Biologics to finalize our testing, pursue regulatory
Hanje Chen, Interface Biologics Inc., Toronto, ON - Business Contact Information in Jigsaw's business directory. Jigsaw's business directory provides complete
Interface Biologics Inc. (Toronto, ON). Emerging and Later Interface Biologics Inc. fabricates smart biomaterials that can be designed to elicit
Trademark information for INTERFACE BIOLOGICS..
4, 2011) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased
INTERFACE BIOLOGICS INCORPORATED Patent applications. Patent application number, Title, Published. 20100055068, GRAFTED POLYMERS AND USES
2004/10/27. VenGrowth backs the next wave of technology for "smart" medical devices with Interface Biologics investment. Toronto company's novel technology
Interface Biologics Inc., MaRS Centre, Discovery District, Toronto, ON. “They go the extra mile…” “We have utilized Caledon for many years, and find their
From 2005 to 2009, Mr. Sullivan was Chief Executive Officer of Interface Biologics , Inc., a developer and marketer of innovative polymer chemistry biomaterials.
Interface Biologics-BASF Future Business Collaborate.
Interface Biologics, Inc Patent applications. Patent application number, Title, Published. 20110271961, SURFACE MODIFYING MACROMOLECULES WITH
Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the
10, 2011) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased
Interface Biologics Inc., a venture-backed commercial stage developer of transformative biomedical-polymer products, today officially
million in venture capital financing, the company announced last week. The $6- million Discovery District Biotech Fund, a joint venture between
Paul Santerre - Chief Scientific Officer at Interface Biologics 2. Matthew Ferguson - Head Researcher at The Sterling Institute, Executive Director at A Canadian
TORONTO—Fresenius Medical Care has executed its option of an exclusive licensing agreement with Interface Biologics Inc. (IBI) following a
Our technologies pave the way for implantable medical devices that are not only biocompatible and bioactive, but potentially bioresponsive--which means they
Interface Biologics, Inc. (Interface) is a therapeutic biomaterials company engaged in developing and producing specialty polymers and polymer additiv.
Interface Biologics (Canada) an early-stage developer of therapeutic biomaterials for use in implantable medical devices closed a $5M Series C financing.
I Incoe Corporation - Interface Biologics - Intertech Rx LLC - Intertek Expert Services - Invibio Inc. - Invivosciences LLC - ITC Corp. J JOA North America
The Medcan Clinic, located in downtown Toronto is a leader in
He currently serves on the Board of Directors of Epocal Inc., and is a past director of Affinium Pharmaceuticals, Insception Biosciences, Interface Biologics and
Interface Biologics Inc., a venture-backed developer of biomedical-polymer products, said it has reached a licensing and supply agreement
Toronto, July 20, 2010 — Interface Biologics Inc. (IBI), a privately held early commercial stage developer of transformative biomedical-polymer technology
Interface Biologics Appoints Art Rosenthal to Chairman of its Board of Directors.
Interface Biologics Inc. announced the appointment of Richard W. Sullivan to the position of President and Chief Executive Officer of the
Interface Biologics, Inc. will be presenting at OneMedForum 2011 on January Interface Biologics is an early commercial stage privately held
Name: